article
Mapping the genome in 3D to reveal new drug targets
Find out how a three-dimensional view of the genome is giving scientists a clearer picture of disease biology and revealing new opportunities for targeted therapies.
List view / Grid view
Multiple Sclerosis (MS)
news
DARG cells may drive neurodegeneration in progressive MS
Scientists have discovered a rare type of brain cell that appears to drive the chronic inflammation seen in progressive multiple sclerosis – which could potentially lead to new disease-modifying therapies.
article
Eye movements as objective biomarkers: accelerating CNS drug development
Measuring disease progression remains one of the biggest hurdles in CNS drug development. Eye movements, now trackable with just a laptop and webcam, are emerging as a sensitive and scalable biomarker that could transform how trials are designed and therapies reach patients.
article
Fighting MS progression: why GPR17 is the target to watch
Despite major advances in multiple sclerosis treatment, stopping disease progression has remained out of reach. Targeting the receptor GPR17 may harness the brain’s own repair system, offering the prospect of genuine remyelination and lasting benefit for patients.
article
Better assays: the key step in moving drugs from lab to clinic
From gene therapy to Long Covid, better assays are helping researchers move promising drug candidates from early studies into clinical trials. Dr Alexandre Lucas explains the technologies, challenges and innovations driving this progress.
article
Inside the Alzheimer’s study backing stem cells, not drugs
In this first-in-human Alzheimer’s study, Wnt-activated autologous stem cells are delivered intracerebroventricularly (directly into the brain) to address neuronal loss, while also reducing amyloid and tau biomarkers and improving cognition. Early data from this regenerative approach could help early drug discovery teams shape target selection, biomarker development and trial design.
news
Autoimmune breakthrough: Egr-1 regulates treg cells in diseases like MS
Scientists have found a key mechanism driving immune regulation in autoimmune diseases like MS and IBD – which could lead to new targeted treatments.
news
Specific HERV expression signatures linked to MS and ALS
The study identified which specific HERVs are important in increasing susceptibility for neurodegenerative diseases.
news
PolTREG begins CAR-Treg development for neuroinflammatory disease
After successful completion of the CAR-Treg preclinical study, the first in-human trial of the candidate to treat MS and ALS will commence.
news
Rare types of helper T cells uncovered
Researchers have created a new T cell atlas which could aid the development of novel drug therapies for immune-mediated diseases.
article
Brain organoids: a fascinating and powerful tool for drug discovery
Human brain organoids are complex in vitro tools derived from stem cells, designed to model the molecular basis of neurodevelopment and the pathogenesis of neurological disorders. By mimicking the function of the human brain, in both health and disease, their application in drug discovery holds significant potential for identifying new…
news
Novel protein function inhibitor regenerated myelin sheaths
Researchers showed that ESI1, or similar compounds, may help to slow or even reverse cognitive losses that can occur during aging.
news
Determining the cellular architecture of multiple sclerosis lesions
Using in situ sequencing, a collaborative research group analysed 260 genes and discovered new sub-structures in MS lesions.
news
New insights about the influence of STAP-1 on immune cell activation
The new findings could lead to a therapeutic target for immune-related disorders, like multiple sclerosis.
news
Investigating neuron-OPC synapses in live tissue
Oligodendrocyte precursor cells and the synapses they form with neurons could be relevant to many disease conditions, including cancer.
